---
title: "Physiological variability in Alzheimer's biomarkers and the mechanistic basis for ratio normalizat"
id: "medrxiv-7-physiological-variability-in-key-alzheimer-s-biomarkers-in-amyloid-positive"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-7-physiological-variability-in-key-alzheimer-s-biomarkers-in-amyloid-positive"
content_type: "clinical_feed_article"
specialty: "Neurology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.18.26363412v1?rss=1"
published_at: "2026-09-21T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Physiological variability in Alzheimer's biomarkers and the mechanistic basis for ratio normalizat
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-7-physiological-variability-in-key-alzheimer-s-biomarkers-in-amyloid-positive
- **Specialty:** [Neurology](https://medichelpline.com/clinical-feed/neurology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.18.26363412v1?rss=1)
- **Published At:** 2026-09-21T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Protein biomarkers in **cerebrospinal fluid (CSF)** and **plasma** are established tools for diagnosing and monitoring neurological disease and are increasingly used in clinical trials to assess therapeutic effects on brain biology. - Physiological differences between individuals (for example, compartment volumes and elimination kinetics) introduce non-disease-related variability in biomarker concentrations that can affect interpretation in trials. - The study analyzed paired baseline CSF and plasma data from four Phase III Alzheimer disease clinical trials (GRADUATE I and II, CREAD and CREAD2) to quantify contributions of physiological versus neurobiological variability to inter-individual differences in commonly used AD biomarkers. - Biomarkers studied included **Aβ40**, **Aβ42**, **p-tau181**, **t-tau**, **NfL**, **GFAP**, **sTREM2**, and **YKL-40**. - A large fraction of inter-individual variability in these amyloid-positive clinical-trial cohorts was attributable to physiological variability rather than neurobiological differences. - Normalizing biomarkers by **Aβ40** or **Aβ42** reduced physiological variability for some biomarkers, but the benefit depended on the biological compartment (CSF vs plasma) and the specific cohort. - The authors present a mechanistic kinetic framework and identify two conditions under which ratio-based normalization is most likely to improve biomarker performance: (1) the target and reference biomarkers strongly share physiological variability, and (2) they maintain independent neurobiological variability. - These conditions explain why **Aβ-based ratios** help for certain biomarkers but are not universally optimal, and they provide a rationale for choosing normalization strategies in clinical-trial biomarker analyses. - The work aims to improve biomarker interpretation in trials by clarifying when ratio-based approaches reduce physiological noise versus when they may not provide benefit. - All authors are employees of F. Hoffmann-La Roche Ltd; datasets were de-identified and come from registered clinical trials (NCT03444870, NCT03443973, NCT02670083, NCT03114657).
## Clinical Analysis & Structured Key Points
Physiological variability in key Alzheimer's biomarkers in amyloid-positive clinical trial cohorts and the mechanistic basis of biomarker ratios | medRxiv Skip to main content Physiological variability in key Alzheimer's biomarkers in amyloid-positive clinical trial cohorts and the mechanistic basis of biomarker ratios Eve Tasiudi , David J Hawellek , Eduardo Aponte , Matteo Tonietto , Holly Soares , Cheikh Diack , Antoine Soubret , Tony Kam-Thong , Benjamin Ribba , View ORCID Profile Marcelo Boareto doi: https://doi.org/10.64898/2026.09.18.26363412 Eve Tasiudi 1 F. Hoffmann-La Roche Ltd; Find this author on Google Scholar Find this author on PubMed Search for this author on this site David J Hawellek 2 F. Hoffmann-La Roche Ltd. Find this author on Google Scholar Find this author on PubMed Search for this author on this site Eduardo Aponte 1 F. Hoffmann-La Roche Ltd; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Matteo Tonietto 1 F. Hoffmann-La Roche Ltd; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Holly Soares 1 F. Hoffmann-La Roche Ltd; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Cheikh Diack 1 F. Hoffmann-La Roche Ltd; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Antoine Soubret 1 F. Hoffmann-La Roche Ltd; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Tony Kam-Thong 1 F. Hoffmann-La Roche Ltd; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Benjamin Ribba 1 F. Hoffmann-La Roche Ltd; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Marcelo Boareto 1 F. Hoffmann-La Roche Ltd; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Marcelo Boareto For correspondence: marcelo.boareto{at}roche.com Abstract Info/History Metrics Data/Code Preview PDF Abstract Background: Protein biomarkers in cerebrospinal fluid (CSF) and plasma have established themselves as essential tools for the diagnosis of neurological disorders and for disease monitoring, thanks to their accuracy and clinical validity. Outside their original intended context of use, protein biomarkers are increasingly used in clinical trials to assess the effects of novel therapies on brain biology. Physiological differences across individuals - such as CSF or plasma volume and elimination kinetics - also contribute to biomarker variability. A deeper understanding of these sources of variability is essential to further improve biomarker interpretation, particularly in clinical trials where populations are by design more homogeneous than in real-world diagnostic settings. This study aimed to quantify the contributions of physiological factors to inter-individual biomarker variability, and to identify the mechanistic basis for why ratio-based normalization can lead to enhanced biomarker performance. Methods: Using a mechanistic kinetic framework and paired CSF and plasma baseline data from four Phase III clinical trials (GRADUATE I and II, CREAD and CREAD2), we quantified physiological and neurobiological contributions (hereafter, physiological and neurobiological variability) to inter-individual variability of commonly used AD biomarkers (Aβ40, Aβ42, p-tau181, t-tau, NfL, GFAP, sTREM2, YKL-40), and evaluated the conditions under which ratio-based normalization can reduce physiological variability. Results: In these amyloid-positive clinical-trial populations, a large fraction of inter-individual variability could be attributed to physiological variability. While normalizing biomarker values by Aβ40 or Aβ42 reduced physiological variability for some biomarkers, the effects of the normalization were compartment-, and cohort-dependent. Using our framework, we identified two conditions under which ratio-based normalization is most likely to improve biomarker performance: (1) the target and reference biomarkers strongly share physiological variability, and (2) they maintain independent neurobiological variability. These conditions provide a mechanistic explanation for why Aβ-based ratios are useful for some biomarkers but are not optimal for others. Discussion: These findings advance our understanding of the sources of biomarker variability in clinical trials and provide a framework for better understanding the mechanistic basis of ratio-based normalization. This work aims to strengthen the utility of using biomarkers by clarifying when and why ratio-based approaches are most informative. Competing Interest Statement All authors are employees of F. Hoffmann-La Roche Ltd. Clinical Trial NCT03444870, NCT03443973 , NCT02670083 , NCT03114657 Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: For all cohorts, participants provided written informed consent, and the studies were conducted in accordance with Good Clinical Practice guidelines and the principles of the Declaration of Helsinki. Detailed descriptions of the study protocols have been previously published for the GRADUATE studies (ClinicalTrials.gov Identifier:, NCT03444870 , NCT03443973 , reference 26) and CREAD studies (ClinicalTrials.gov Identifier: NCT02670083 , NCT03114657 , reference 27). All datasets analyzed in this study were fully de-identified prior to access and analysis. The manuscript does not present any data at individual level. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability For clinical trial studies, qualified researchers may request access to individual patient-level clinical data through a data request platform. At the time of writing, this request platform is Vivli (vivli.org/ourmember/roche/). Up-to-date details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents can be found at go.roche.com/data_sharing. Anonymized records for individual patients across more than one data source external to Roche cannot, and should not, be linked because of a potential increase in risk of patient re-identification. Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license . Back to top Previous Next Posted September 21, 2026. Download PDF Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Physiological variability in key Alzheimer's biomarkers in amyloid-positive clinical trial cohorts and the mechanistic basis of biomarker ratios Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Physiological variability in key Alzheimer's biomarkers in amyloid-positive clinical trial cohorts and the mechanistic basis of biomarker ratios Eve Tasiudi , David J Hawellek , Eduardo Aponte , Matteo Tonietto , Holly Soares , Cheikh Diack , Antoine Soubret , Tony Kam-Thong , Benjamin Ribba , Marcelo Boareto medRxiv 2026.09.18.26363412; doi: https://doi.org/10.64898/2026.09.18.26363412 Share This Article: Copy Citation Tools Physiological variability in key Alzheimer's biomarkers in amyloid-positive clinical trial cohorts and the mechanistic basis of biomarker ratios Eve Tasiudi , David J Hawellek , Eduardo Aponte , Matteo Tonietto , Holly Soares , Cheikh Diack , Antoine Soubret , Tony Kam-Thong , Benjamin Ribba , Marcelo Boareto medRxiv 2026.09.18.26363412; doi: https://doi.org/10.64898/2026.09.18.26363412 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (619) Allergy and Immunology (903) Anesthesia (335) Cardiovascular Medicine (4832) Dentistry and Oral Medicine (479) Dermatology (419) Emergency Medicine (651) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1633) Epidemiology (15980) Forensic Medicine (33) Gastroenterology (1206) Genetic and Genomic Medicine (7067) Geriatric Medicine (734) Health Economics (1067) Health Informatics (5061) Health Policy (1438) Health Systems and Quality Improvement (1776) Hematology (587) HIV/AIDS (1347) Infectious Diseases (except HIV/AIDS) (16310) Intensive Care and Critical Care Medicine (1176) Medical Education (671) Medical Ethics (155) Nephrology (727) Neurology (7294) Nursing (369) Nutrition (1084) Obstetrics and Gynecology (1244) Occupational and Environmental Health (1006) Oncology (3617) Ophthalmology (1055) Orthopedics (398) Otolaryngology (458) Pain Medicine (474) Palliative Medicine (140) Pathology (709) Pediatrics (1805) Pharmacology and Therapeutics (739) Primary Care Research (769) Psychiatry and Clinical Psychology (5921) Public and Global Health (9772) Radiology and Imaging (2433) Rehabilitation Medicine and Physical Therapy (1456) Respiratory Medicine (1250) Rheumatology (643) Sexual and Reproductive Health (773) Sports Medicine (581) Surgery (783) Toxicology (107) Transplantation (305) Urology (293)
## Related Clinical Research

- [Orexin agonist ALKS 7290 shows ADHD symptom improvement in early Phase 1 trial](https://medichelpline.com/clinical-feed/stat-news-0-stat-alkermes-orexin-agonist-shows-potential-to-treat-adhd-in-early-stage-trial.md)
- [Kennedy launches ARPA-H initiative to accelerate autism diagnoses and research](https://medichelpline.com/clinical-feed/stat-news-0-kennedy-announces-new-effort-to-speed-up-autism-diagnoses.md)
- [Antihypertensive Drug Class and Risk of Incident Alzheimer’s Disease and Related Dementias: Replic](https://medichelpline.com/clinical-feed/medrxiv-17-antihypertensive-medication-class-and-incident-alzheimers-disease-and-related.md)
- [Laromestrocel (Lomecel‑B) reduces neuroinflammation and preserves brain volume and cognition in mi](https://medichelpline.com/clinical-feed/medrxiv-1-laromestrocel-preserves-brain-volume-and-cognitive-function-in-alzheimers.md)
- [Choroid Plexus Calcification in Lateral, Third, and Fourth Ventricles: Links to Aging, Brain Struc](https://medichelpline.com/clinical-feed/biorxiv-21-regional-choroid-plexus-calcifications-and-their-associations-with-aging-brain.md)

## Navigation
- [← Back to Neurology Feed](https://medichelpline.com/clinical-feed/neurology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.